Vericiguat · Verquvo

Small molecule

Also known as BAY1021189

Approvedregulatory verdict

Evidence outlook

Approved: Heart Failure

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CA
  • VERQUVO (vericiguat) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent heart failure decompensation event requiring hospitalization and/or intravenous diuretic therapy. VERQUVO should be used in combination with standard of care therapy for heart failure. VERQUVO should be initiated under the supervision of a healthcare professional who is experienced in the management of heart failure (see 4.1 Dosing Considerations).
Product first approved 2023Health Canada
EU
  • Treatment of symptomatic chronic heart failure
Product first approved 2021EMA
JP
  • Treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure)
Product first approved 2021PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Heart Failure
Phase 2/3 (1)
Heart Failure
NCT05714085 · Merck Sharp & Dohme LLC
2023-05-31 – 2032-05-12 · Heart Failure, Left Ventricular Systolic Dysfunction
What this study did
Phase 2 (11)
Heart Failure
NCT06601465 · University of Alberta
2025-06-03 – 2028-07-16 · Heart Failure, Cognitive Impairment
What this study did
NCT06195930 · Bayer
2024-04-18 – 2024-07-29 · Chronic Heart Failure With Reduced Ejection Fraction
What this study did
NCT03547583 · Bayer
2018-06-15 – 2019-11-04 · Chronic Heart Failure With Preserved Ejection Fraction
What this study did
Other / comorbidity
NCT07715279 · West China Hospital
2026-09-24 – 2029-11-30 · Calcific Aortic Valve Disease, AORTIC VALVE DISEASES, Aortic Valve Stenosis
What this study did
NCT06320951 · University of Alabama at Birmingham
2026-12-01 – 2029-04-30 · Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
What this study did
NCT05806138 · Memorial Sloan Kettering Cancer Center
2023-07-17 – 2028-07-17 · Breast Cancer, Cardiac Dysfunction
What this study did
NCT05697640 · Charite University, Berlin, Germany
2023-06-22 – 2026-12-31 · Post-COVID ME/CFS
What this study did
NCT06415227 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2025-02-10 – 2026-07-13 · Vasospastic Angina
What this study did
NCT05711719 · Johns Hopkins University
2023-06-16 – 2025-11-18 · Metabolic Syndrome, Coronary Microvascular Dysfunction
What this study did
Phase 1 (9)
Heart Failure
NCT07444398 · Khawaja Danish Ali
2026-01-01 – 2026-03-31 · Decompensated Heart Failure
What this study did
NCT06474208 · Bayer
2024-07-01 – 2024-09-30 · Heart Failure
What this study did
Other / comorbidity
NCT03504982 · Bayer
2018-05-17 – 2019-02-26 · Coronary Artery Disease
What this study did
NCT03255512 · Bayer
2017-08-17 – 2018-03-23 · Coronary Artery Disease
What this study did
NCT03145038 · Bayer
2017-05-16 – 2017-10-09 · Pharmacokinetics
What this study did
NCT02617550 · Bayer
2015-11-18 – 2016-08-11 · Coronary Artery Disease
What this study did
Phase 4 (9)
Heart Failure
NCT07405944 · University Medical Centre Ljubljana
2025-11-01 – 2027-12-31 · Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure
What this study did
NCT07697833 · National Institute of Cardiovascular Diseases, Pakistan
2026-07-15 – 2027-07-31 · Heart Failure With Reduced Ejection Fraction (HFrEF)
What this study did
NCT05704478 · University of Colorado, Denver
2024-01-01 – 2027-03-31 · Heart Failure
What this study did
NCT06812546 · Dongying Zhang
2025-04-01 – 2026-12-30 · Heart Failure, Acute Myocardial Infarction (AMI), Acute Heart Failure (AHF)
What this study did
NCT06671990 · Finn Gustafsson
2024-12-01 – 2026-01-31 · Heart Failure, Pulmonary Arterial Hypertension
What this study did
NCT05420012 · Josef Stehlik
2023-05-01 – 2024-10-24 · Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
What this study did
Other / comorbidity
NCT05812755 · Vanderbilt University Medical Center
2023-05-19 – 2029-07 · Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular Inflammation
What this study did
NCT07668739 · Daejeon St. Mary's hospital
2026-07-01 – 2028-05-31 · HFrEF, Tricuspid Regurgitation (TR)
What this study did
Early phase / not applicable (3)
Heart Failure
NCT07047547 · Guangdong Provincial People's Hospital
2025-06-01 – 2026-06-01 · Hemodialysis Complication, Heart Failure
What this study did
Other / comorbidity
NCT07594509 · Nanjing Medical University
2026-05-31 – 2030-12-31 · Cardio Vascular Disease, Cardiopulmonary Bypass
What this study did
NCT06239974 · The University of Hong Kong
2024-09-01 – 2027-08-31 · Chest Pain
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Heart Failure: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Vericiguat (Verquvo): this drugApprovedSmall moleculeSoluble guanylate cyclasePartial signal
NCT02861534: CV death or first HF hospitalization, vericiguat vs placebo: 897 of 2526 (35.5%) vs 972 of 2524 (38.5%) over a median 10.8 months; HR 0.90 (95% CI 0.82 to 0.98), P = 0.02. Met.
NCT05093933: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years (Up to approximately 36 months (from randomization to the primary completion data cutoff)): Vericiguat 11.3 Pts. with event/100 patient-yrs at risk | Placebo 12.2 Pts. with event/100 patient-yrs at risk missed
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT04564742: Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo)
NCT03619213: Primary composite outcome (worsening heart failure or cardiovascular death): dapagliflozin 16.4% vs placebo 19.5%; hazard ratio 0.82 (95% CI 0.73-0.92, p<0.001)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03057951: Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction.
NCT03057977: Primary composite outcome (cardiovascular death or hospitalization for worsening heart failure) at median 16 months: 19.4% (361/1863) with empagliflozin vs 24.7% (462/1867) with placebo; hazard ratio 0.75 (95% CI 0.65-0.86), P<0.001
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT03037931: Primary endpoint, hierarchical composite of death and heart failure hospitalization at 12 months and change in 6-minute walk distance at 6 months (significance level 0.01): unmatched win ratio 1.10 (99% CI 0.99 to 1.23), Wilcoxon-Mann-Whitney P=0.02. Components, ferric carboxymaltose vs placebo: deaths 131 (8.6%) vs 158 (10.3%); heart failure hospitalizations 297 vs 332; 6-minute walk change +8 vs +4 m. missed
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT04435626: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2Weak signalFeatured results are non-efficacy only in this race
Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Isosorbide Dinitrate / Hydralazine (BiDil)ApprovedSmall moleculeHydralazine/isosorbide dinitrate (fixed combination)Partial signal
NCT00047775: Primary composite score (all-cause mortality, first heart-failure hospitalization, quality of life) favoured isosorbide dinitrate/hydralazine vs placebo (p=0.021); the trial stopped early for a 43% reduction in all-cause mortality (p=0.012) (BiDil label, A-HeFT).
Ivabradine (Corlanor)
ApprovedUS marketing discontinued
Small moleculeIf (funny) channelReliable signal
NCT02441218: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. (All over the study (up to 42 months).): Ivabradine 793 participants | Placebo 937 participants
Riociguat (Adempas)
Approved(overall)
Small moleculeSoluble guanylate cyclase
Reliable signal(overall)
No reviewed efficacy summary in this indication
Sacubitril / Valsartan (Entresto)ApprovedSmall moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01035255: Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization (up to 51 months): LCZ696 — Primary Composite: 914 participants; CV death: 558 participants; 1st HF Hospitalization: 537 participants | Enalapril — Primary Composite: 1117 participants; CV death: 693 participants; 1st HF Hospitalization: 658 participants
NCT01920711: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. (Total follow up time (up to 57 months)): LCZ696 — Primary Composite Events: 894 Events; Total Hospitalizations for heart failure: 690 Events; Cardiovascular death: 204 Events | Valsartan — Primary Composite Events: 1009 Events; Total Hospitalizations for heart failure: 797 Events; Cardiovascular death: 212 Events missed
Sotagliflozin (Inpefa)ApprovedSmall moleculeSGLT1/2 (dual)Partial signal
NCT03315143: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 30 months): Sotagliflozin 5.6 events per 100-person years | Placebo 7.5 events per 100-person years
NCT03521934: Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF) (Up to 21.9 months): Sotagliflozin 51 events per 100-person years | Placebo 76.3 events per 100-person years
Torsemide (Soaanz)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
AlprostadilPhase 3Small moleculeProstaglandin E1 receptornot yet gradedNo reviewed efficacy summary in this indication
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
CardiAMPPhase 3Cell therapyCardiac cell therapyPartial signal
NCT02438306: 3-tiered Finkelstein-Schoenfeld primary endpoint at 12 months (interim, 102 of eventual 125 patients): Tier 1 all-cause death 5.6% CardiAMP vs 5.3% control (P=.42); Tier 2 MACCE 16.7% vs 15.8% (P=.82); Tier 3 6MWT change +36.1m vs +33.4m (P=.6) - none reached significance; DSMB futility review concluded the trial was unlikely to meet its primary endpoint missed
CoramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ferric Derisomaltose (Monoferric / Monofer)Phase 3Iron Complex (iv)Iron repletionWeak signal
NCT00537186: Single-arm, open-label safety study with no comparator and no formal efficacy test. All registered primary outcomes are safety measures (adverse events, serious adverse events, physical examination, vital signs, laboratory tests). A published pilot study that appears to be this trial (Hildebrandt et al. 2010, n=20) reported no treatment-related adverse reactions and no clinically significant changes in laboratory safety tests or vital signs over 8 weeks.
HiCM-188 (allogeneic iPSC-Cardiomyocytes)Phase 3Cell therapyCardiac cell therapyPartial signalNo reviewed efficacy summary in this indication
Icodextrin (peritoneal Ultrafiltration) (Extraneal)Phase 3Glucose Polymer Solution (peritoneal Dialysis)Peritoneal ultrafiltrationWeak signal
NCT00368641: All-cause Hospitalization (Unadjusted) (6 to 24 months): Intervention Group 5.33 hospitalizations per year (95% CI 3.13 to 9.05) vs Standard Therapy 1.69 hospitalizations per year (95% CI 0.95 to 2.99)
Levosimendan (Simdax)Phase 3Small moleculeCardiac troponin C (calcium sensitizer)Partial signal
NCT00348504: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P = .40). missed
NCT00048425: REVIVE II, n=600: 5-day clinical-course composite primary endpoint improved 33% more often and worsened 26% less often with levosimendan vs placebo (p=0.015).
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
Mosliciguat
Phase 3(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication
Omecamtiv MecarbilPhase 3Small moleculeCardiac myosin (activator)Reliable signal
NCT02929329: Time to Cardiovascular Death or First Heart Failure Event (From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.): Omecamtiv Mecarbil 37% vs Placebo 39.1%
NCT03759392: Change in Peak Oxygen Uptake on Cardiopulmonary Exercise Testing From Baseline to Week 20 (Baseline and Week 20): Omecamtiv Mecarbil -0.239 mL/min/kg (Standard Error 0.1718) vs Placebo 0.207 mL/min/kg (Standard Error 0.2412) missed
OPC-61815 (Samtasu)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT03772041: Change From Baseline in Body Weight (Baseline, Day 6): OPC-61815 Injection 16 mg -1.67 kg (95% CI -1.93 to -1.41) vs Tolvaptan Tablet 15mg -1.36 kg (95% CI -1.62 to -1.1)
QiShenYiQiPhase 3BotanicalTraditional Chinese medicine (multi-component)Partial signalNo reviewed efficacy summary in this indication
Recombinant Human Neuregulin-1 (rhNRG-1) (Neucardin)Phase 3Protein / enzyme therapeuticErbB2/ErbB4 (neuregulin pathway)Partial signalNo reviewed efficacy summary in this indication
Rexlemestrocel-LPhase 3Cell therapyMesenchymal precursor cells (MPCs)Weak signalFeatured results are safety only in this race
Sotatercept (Winrevair)Phase 3Protein / enzyme therapeuticActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Samsca)Phase 3Small moleculeVasopressin V2 receptorPartial signal
NCT00071331: All-cause mortality: tolvaptan 25.9% vs placebo 26.3% (HR 0.98, 95% CI 0.87-1.11, P=.68). Composite of CV death or HF hospitalization: tolvaptan 42.0% vs placebo 40.2% (HR 1.04, 95% CI 0.95-1.14, P=.55). missed
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
DanicamtivPhase 2/3Small moleculeCardiac myosin (activator)Weak signal
NCT03447990: Troponin I increase: 3/12 danicamtiv vs 0/12 placebo in SAD cohorts; 7/30 danicamtiv vs 0/10 placebo in MAD cohorts.
IstaroximePhase 2/3Small moleculeNa-K ATPase / SERCA2aPartial signal
NCT02617446: Change in E/Ea Ratio (24 hours): Istaroxime 0.5 µg/kg/Min -4.55 Unitless ratio (95% CI -6.05--3.04) vs Placebo Cohort I -1.55 Unitless ratio (95% CI -3.77-0.67) vs Istaroxime 1.0 µg/kg/Min -3.16 Unitless ratio (95% CI -4.09--2.24) vs Placebo Cohort II -1.08 Unitless ratio (95% CI -2.30-0.13); p=0.029 (Istaroxime 0.5 µg/kg/Min vs Placebo Cohort I), p=0.009 (Istaroxime 1.0 µg/kg/Min vs Placebo Cohort II)
AC01Phase 2Small moleculeGhrelin receptorWeak signalNo reviewed efficacy summary in this indication
ADR-002KPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
Bucindolol (Gencaro)Phase 2Small moleculeBeta-1/beta-2 adrenergic receptor (genotype-guided)Partial signal
NCT01970501: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of Stable Sinus Rhythm (SR) on Study Drug [End of Treatment Week 24]. (end of treatment week 24): Bucindolol Hydrochloride 35.9 days (IQR 9 to 53) vs Metoprolol Succinate 33.2 days (IQR 6 to 47) missed
CDR132LPhase 2RNA / oligonucleotidemicroRNA-132Weak signalFeatured results are safety only in this race
Corteria COR-1167Phase 2PeptideCorticotropin-releasing factor receptor 2not yet gradedNo reviewed efficacy summary in this indication
DelocamtenPhase 2Small moleculeCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
DeramiocelPhase 2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HRS-9057Phase 2Small moleculeVasopressin V1a/V2 receptor (dual)Weak signalNo reviewed efficacy summary in this indication
HU6Phase 2Small moleculeMitochondrial uncouplingPartial signal
NCT05284617: Weight change at 3 months (450 mg HU6 dose): -6.8 lb from baseline (p<0.0001); -6.3 lb vs placebo (p=0.003)
Jia Shen TabletPhase 2BotanicalMulti-target (ginsenoside)Weak signalNo reviewed efficacy summary in this indication
JK07Phase 2Biologic (subtype unspecified)HER3 × ErbB4Weak signalFeatured results are safety only in this race
JTT-861Phase 2Small moleculePyruvate dehydrogenasePartial signalNo reviewed efficacy summary in this indication
Mavacamten (Camzyos)Phase 2Small moleculeCardiac myosin (inhibitor)Weak signalFeatured results are safety only in this race
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationWeak signal
NCT04826159: Primary, resting cardiac PCr/ATP change from baseline (single arm, no comparator): Part 1 (type 2 diabetes and obesity) +0.39 (95% CI 0.16 to 0.62; P=0.002); Part 2 (with HFpEF) +0.15 (95% CI 0.03 to 0.26; P=0.02). Dobutamine-stress PCr/ATP (Part 1) is not reported in the abstract.
Nurandociguat
Phase 2(overall)
Small moleculeSoluble guanylate cyclase
Partial signal(overall)
No reviewed efficacy summary in this indication
PexerelgonPhase 2Small moleculeRelaxin receptor (RXFP1) / relaxinPartial signalNo reviewed efficacy summary in this indication
PF-07328948Phase 2Small moleculeBranched-chain ketoacid dehydrogenase kinase (BDK)not yet gradedNo reviewed efficacy summary in this indication
Praliciguat
Phase 2(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication
R2R01Phase 2PeptideRelaxin receptor (RXFP1) / relaxinWeak signalNo reviewed efficacy summary in this indication
RibupatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Safiglipron (HRS-7535)Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TovinontrinePhase 2Small moleculePDE9Partial signalNo reviewed efficacy summary in this indication
Umiposgene Parvec (AB-1002)Phase 2Gene therapy / editingProtein inhibitor-1 (gene therapy)Weak signal
NCT04179643: Phase 1 first-in-human trial of a single antegrade coronary infusion of AB-1002 in NYHA III non-ischemic heart failure: no adverse events or serious adverse events were attributed by the investigators to the study treatment. Mean left ventricular ejection fraction rose from 30.5% at baseline to 42.2% at 12 months in cohort 1 and from 24.5% to 36.7% in cohort 2, and all patients with baseline and 12-month assessments had an improvement in ejection fraction of at least 5%.
XTR003Phase 2Diagnostic (pet Tracer)Myocardial fatty-acid metabolism (PET imaging)not yet gradedNo reviewed efficacy summary in this indication
AAV1.SERCA2aPhase 1/2Gene therapy / editingSERCA2a (gene therapy)not yet gradedNo reviewed efficacy summary in this indication
HS-001Phase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
HucMSC Intramyocardial TherapyPhase 1/2Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
PolyCorePhase 1/2SolutionPeritoneal ultrafiltrationnot yet gradedNo reviewed efficacy summary in this indication
Anhui HygeianCells EE001Phase 1Biologic (subtype unspecified)Cardiac cell therapyWeak signalNo reviewed efficacy summary in this indication
SK-08
Phase 1(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 14 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Verquvo (Vericiguat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
Phase 4Heart FailureNot yet recruiting
Est. primary completion 2027-05-15 · NCT07697833 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Heart FailureRecruiting
Est. primary completion 2027-07-31 · NCT07405944 · CT.gov ↗
What to watch
August 2027 (1)
Early phase / not applicableChest PainRecruiting
Est. primary completion 2027-08-31 · NCT06239974 · CT.gov ↗
What to watch
2028 (6)
April 2028 (1)
Phase 2Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, ObesityNot yet recruiting
Est. primary completion 2028-04-30 · NCT06320951 · CT.gov ↗
What to watch
May 2028 (1)
Phase 4HFrEF, Tricuspid Regurgitation (TR)Not yet recruiting
Est. primary completion 2028-05-31 · NCT07668739 · CT.gov ↗
What to watch
July 2028 (3)
Phase 4Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular InflammationRecruiting
Est. primary completion 2028-07 · NCT05812755 · CT.gov ↗
What to watch
Phase 2Heart FailureRecruiting
Est. primary completion 2028-07-16 · NCT06601465 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Cardiac DysfunctionActive not recruiting
Est. primary completion 2028-07-17 · NCT05806138 · CT.gov ↗
What to watch
December 2028 (1)
Early phase / not applicableCardio Vascular Disease, Cardiopulmonary BypassNot yet recruiting
Est. primary completion 2028-12-31 · NCT07594509 · CT.gov ↗
What to watch
2029 (2)
August 2029 (1)
Phase 2/3Heart FailureRecruiting
Est. primary completion 2029-08-20 · NCT05714085 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Calcific Aortic Valve Disease, AORTIC VALVE DISEASES, Aortic Valve StenosisRecruiting
Est. primary completion 2029-10-31 · NCT07715279 · CT.gov ↗
What to watch

See the full readout calendar ↗